Biomarkers for Alzheimer’s Disease Drug Development

This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer’s disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer’s disease, cutting-edge developments in neuropathology and their relevance for Alzheimer’s disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

 

Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field. 

PART I: The need for Alzheimer’s Disease Biomarkers

1. Epidemiology of Dementia: The Burden on Society, the Challenges for Research

Frank J. Wolters and M. Arfan Ikram

 

2. Population-based Approaches to Alzheimer’s Disease Prevention

Robert Perneczky

 

3. Systems Biology Methods for Alzheimer’s Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials

Juan I. Castrillo, Simone Lista, Harald Hampel, and Craig W. Ritchie

 

 

PART II: Innovative Approaches to Cerebrospinal Fluid Biomarker Discovery

4. CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform

Paul L. Wood and Randall L. Woltjer

 

5. CSF N-glycomics using MALDI MS Techniques in Alzheimer’s Disease

Angelo Palmigiano, Angela Messina, Rosaria Ornella Bua, Rita Barone, Luisa Sturiale,  Mario Zappia, and  Domenico Garozzo

  6. MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid Johannes Denk and Holger Jahn

 

 

Part III: Novel Blood-based Biomarkers

7. Validation of a Chemiluminescence Immunoassay for Measuring  Amyloid-ß in Human Blood Plasma

Jonathan Vogelgsang, Jens Wiltfang, and Hans-W. Klafki

 

8. Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer’s Disease Research

Raúl González-Domínguez, Álvaro González-Domínguez, Ana Sayago, and Ángeles Fernández-Recamales

 

9. Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases

Filippo Baldacci, Simone Lista, Sid E. O’Bryant, Roberto Ceravolo, Nicola Toschi, and Harald Hampel,

 

 

Part IV: Magnetic Resonance Imaging Methods

10. Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development

Stefan Holiga, Ahmed Abdulkadir, Stefan Klöppel, and Juergen Dukart

 

11. Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies

Carles Falcon, Grégory Operto, José Luis Molinuevo, and Juan Domingo Gispert

 

12. Hybrid PET-MRI in Alzheimer’s Disease Research

Ismini C. Mainta, Maria I. Vargas , Sara Trombella, Giovanni B. Frisoni, Paul G. Unschuld, Valentina Garibotto

 

Part V: Molecular Imaging Approaches

13. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers

Silvia Morbelli and Matteo Bauckneht

 

14. The use of ¹⁸F-FDG PET in the Diagnostic Workup of Alzheimer’s Dementia

Marion M. Ortner

 

15. Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography

Tessa Timmers, Bart N.M. van Berckel, Adriaan Lammertsma, and Rik Ossenkoppele

 

16. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach

Elena Rodriguez-Vieitez and Agneta Nordberg

 

Part VI: Neuropathology

17. Unbiased Lipidomics and Metabolomics of Human Brain Samples

Giuseppe Astarita, Matteo Stocchero, and Giuseppe Paglia

 

18. Neuropathological Assessment as an Endpoint in Clinical Trial Design

Steve Gentleman and Alan King Lun Liu

 

 

Part VII Genomic Methods

19. Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery

Petros Takousis

 

20. Telomere length shortening in Alzheimer’s disease – procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study
Yiqiang Zhan, Sara Hägg

 

21. Quantifying miRNA Deregulation in Alzheimer’s Disease

Ana L. Cardoso and Joana R. Guedes

 

Part VIII: Preclinical Research

22. Imaging of Microglial Activation in Alzheimer’s Disease by [¹¹C]PBR28 PET

Cornelius K. Donat, Nazanin Mirzaei, Sac-Pharm Tang, Paul Edison, and Magdalena Sastre

 

23. In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models

Marc Aurel Busche

 

 

Part IX: Related concepts: Cognitive Testing and Advanced Analytics

24. Cognitive Assessment in Alzheimer’s Disease Clinical Trials

Geraint Price

 

25. Data Mining and Machine Learning Methods for Dementia Research

Rui Li